A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial
Abstract Objectives The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous Prolastin®(plasma-purified alpha-1 antitrypsin) reduces circulating plasma lev...
Main Authors: | Natalie L. McEvoy, Jennifer L. Clarke, Oliver J. Mc Elvaney, Oisin F. Mc Elvaney, Fiona Boland, Deirdre Hyland, Pierce Geoghegan, Karen Donnelly, Oisin Friel, Ailbhe Cullen, Ann M. Collins, Daniel Fraughen, Ignacio Martin-Loeches, Martina Hennessy, John G. Laffey, Noel G. Mc Elvaney, Gerard F. Curley |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Trials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13063-021-05254-0 |
Similar Items
-
Diagnosing α1-antitrypsin deficiency: how to improve the current algorithm
by: Noel G. McElvaney
Published: (2015-03-01) -
Prone positioning improves oxygenation and lung recruitment in patients with SARS-CoV-2 acute respiratory distress syndrome; a single centre cohort study of 20 consecutive patients
by: Jennifer Clarke, et al.
Published: (2021-01-01) -
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
by: Caitriona McLean, et al.
Published: (2009-01-01) -
Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
by: Noel G. McElvaney, et al.
Published: (2013-03-01) -
A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19
by: Oliver J McElvaney, et al.
Published: (2020-11-01)